Document Detail


Miller Fisher syndrome and plasmapheresis.
MedLine Citation:
PMID:  12460409     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Treatment for Miller Fisher syndrome (MFS) is controversial, and even the natural history and prognosis are not fully understood. We retrospectively reviewed our cases of MFS for the last 3 years. The analysis of 4 MFS cases revealed that we had performed plasmapheresis or additional immunotherapy to each of 4 patients, and their symptoms resolved for up to 50 days after the onset (ataxia improved 20-35 days and ophthalmoplegia for 25-50 days) except for 1 patient, and that Guillain-Barré syndrome had been diagnosed in 1 patient who had developed profound muscle weakness. We also discovered that MFS patients had a deviated T-helper Type-1 (Th1)/T-helper Type-2 (Th2) polarization and that plasmapheresis can shift Th2-dominant status to Th1-dominant status in patients with MFS. Although plasmapheresis may remove humoral factors, including anti-GQ1b, and may induce a shift of the Th1/Th2 cytokine-producing cell balance in peripheral blood, the therapeutic rationale has not yet been established. Therefore, controlled clinical trials are required to show whether plasmapheresis leads to earlier recovery with fewer neurologic deficits in patients with MFS.
Authors:
Chiaki Kambara; Hidenori Matsuo; Takayasu Fukudome; Hirofumi Goto; Noritoshi Shibuya
Related Documents :
10657409 - Identification of patients at risk for periprocedural neurological deficits associated ...
8471189 - Acute amitriptyline withdrawal and hyponatraemia. a case report.
7113659 - Clinical prognosis of patients with diagnosed chronic solvent intoxication.
15364689 - Multiple myeloma invasion of the central nervous system.
7895759 - Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with x-chromosomal adrenole...
879949 - Encephalopathy induced by oral hypoglycemic drugs.
11166459 - Clonality analysis using x-chromosome inactivation patterns by humara-pcr assay in fema...
1364169 - Does c-reactive protein modulate t-lymphocyte function in methotrexate-treated rheumato...
21802259 - Features of acute dwi abnormalities related to status epilepticus.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis     Volume:  6     ISSN:  1091-6660     ISO Abbreviation:  Ther Apher     Publication Date:  2002 Dec 
Date Detail:
Created Date:  2002-12-03     Completed Date:  2003-03-20     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9706703     Medline TA:  Ther Apher     Country:  United States    
Other Details:
Languages:  eng     Pagination:  450-3     Citation Subset:  IM    
Affiliation:
Department of Neurology, Kawatana National Hospital, Nagasaki, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Autoantibodies / blood
Gangliosides / immunology
Humans
Interferon-gamma / blood
Interleukin-4 / blood
Male
Miller Fisher Syndrome / immunology,  therapy*
Plasma Exchange
Plasmapheresis*
Retrospective Studies
Th1 Cells / metabolism
Th2 Cells / metabolism
Chemical
Reg. No./Substance:
0/Autoantibodies; 0/Gangliosides; 207137-56-2/Interleukin-4; 68652-37-9/GQ1b ganglioside; 82115-62-6/Interferon-gamma

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic antibody-associated vas...
Next Document:  Plasma exchange for hypertriglyceridemic acute necrotizing pancreatitis: report of two cases.